Registration is now open for two online forums dedicated to bacteriophages and phage therapy. The Boston Bacteriophage Therapy Summit 2020 will take place on August 27-28, 2020, and the Oxford Phages 2020 Virtual Conference will take place on September 9-10, 2020.
Studies in a cell model have shown great potential for phage therapy in the treatment of meningitis caused by pathogenic Escherichia coli with the K1 capsular antigen.
The CURE project is a multidisciplinary initiative that began in 2017. The project's goal is to use bacteriophages to restore the balance of the respiratory microbiota and normalize immune function in patients with asthma.
On May 14, 2020, the online conference "ANTIBIOTIC THERAPY 2020 – Modern Theory and International Practice" will be held. Andrey Valerievich Voznyak, Associate Professor of the Department of Pediatrics No. 1 at the Danylo Halytsky Lviv National Medical University, will present a paper entitled "Bacteriophages as an Alternative to Antibiotic Therapy in Pediatric Practice."
An experimental nasal DNA vaccine against COVID-19 has been developed in Canada. The DNA is delivered via a bacteriophage to respiratory cells, where it triggers the synthesis of harmless, but coronavirus-like particles that trigger an immune response.
German researchers have "taught" bacteriophages to neutralize the influenza virus and prevent it from entering target cells. Now, scientists have begun similar experiments to neutralize the new SARS-CoV-2 coronavirus.
GINA has issued recommendations for individuals with bronchial asthma regarding their behavior during the COVID-19 coronavirus epidemic.
Little is known about the therapeutic use of bacteriophages in South America. To address this, The Lancet published a comprehensive review devoted to the history of phage therapy in Brazil, which flourished during the 1920s, the "golden age" of bacteriophages worldwide.
Now, more than ever, people are concerned about hand hygiene. The reason is well known: the infamous novel coronavirus SARS-CoV-2. To avoid infection, doctors and virologists advise not only washing your hands frequently and thoroughly with soap, but also using hand sanitizers.
Scientists studying bacteriophages are discussing whether bacterial viruses can somehow help in the situation that has arisen worldwide due to the spread of COVID-19, the disease caused by the new coronavirus SARS-CoV-2.
The negative impact of plastic on marine ecosystems is well known. But Irish scientists recently discovered another problem posed by plastic drifting with ocean currents: it carries bacterial genes that promote antibiotic resistance.
The widespread use of bacteriophages as monotherapy for severe infections is not yet possible for various reasons, but it should be taken into account that their use in combination with antibiotics can significantly increase the effectiveness of treatment.
Patients with severe Staphylococcus aureus infection received intravenous bacteriophage injections twice daily for 14 days. No adverse reactions to the bacteriophage administration were observed from the first day of therapy through 90 days of follow-up.
Scientists have isolated from various sources a number of previously undescribed bacteriophages that are unusually large in size, as well as a large genome that encodes variants of the CRISPR-Cas bacterial immunity system.
Bacteriophages will be studied on the International Space Station. A new NASA research project will examine the effects of microgravity and radiation on the interactions between phages and bacteria.
To prevent uncontrolled phage proliferation in the host organism, they must be destroyed immediately after interaction with the target bacteria. The photothermal properties of gold nanoparticles can be used for this purpose.
In 2019, a 62-year-old American man became the first patient at the renowned Mayo Clinic to receive phage therapy for an antibiotic-resistant infection. The therapy proved effective.
A Phase 1b clinical trial will study the use of the phage preparation LBP-EC01 in urinary tract infections caused by E. coli . In addition to its natural lytic activity, the preparation has DNA-targeted CRISPR-Cas3 activity.
